Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection

Figure 1 SVR12 in the immediate treatment arm. ¹Includes the patient with genotype 1a infection; ²On-treatment HCV RNA ≥ LLOQ after < LLOQ, or increased > 1 log₁₀ over nadir; ³Posttreatment HCV RNA ≥ LLOQ after < LLOQ without detectable target at EOT. EOT: End of treatment; HCV: Hepatitis C virus; LLOQ: Lower limit of quantitation; SVR12: Sustained virologic response at post-treatment week 12.

Figure 2 SVR12 according to selected baseline characteristics in the immediate treatment arm. HCV: Hepatitis C virus; SVR12: Sustained virologic response at posttreatment week 12.

Figure 3 SVR12 in the placebo-deferred treatment arm. ¹On-treatment HCV RNA ≥ LLOQ after < LLOQ, or increased >1 log₁₀ over nadir; ²HCV RNA < LLOQ (TND) at EOT followed by HCV RNA ≥ LLOQ at any follow-up visit; ³Other nonresponders included patients who had HCV RNA < LLOQ (TND) at EOT, but with missing posttreatment week 12 data; ⁴Death, not considered related to study therapy (stab wound). EOT: End of treatment; HCV: Hepatitis C virus; LLOQ: Lower limit of quantitation; SVR12, Sustained virologic response at post-treatment week 12.

Figure 4 SVR12 according to selected baseline characteristics in the placebo-deferred treatment arm¹. ¹Reasons for patients not achieving SVR12 included virologic breakthrough (n = 7), relapse (n = 1) or other (n = 1; death, not considered related to study therapy). HCV: Hepatitis C virus; SVR12: Sustained virologic response at post-treatment week 12.